Patents by Inventor Edward D. S. Kerslake

Edward D. S. Kerslake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preserved cyclodextrin-containing compositions
    Publication number: 20040175435
    Abstract: Compositions including a liquid medium, a cyclodextrin component and a preservative component which has a reduced tendency to being complexed with the cyclodextrin component. In one embodiment, the preservative component is a chlorite component. Active components, such as pharmaceutically active components or drugs, preferably are included in the compositions.
    Type: Application
    Filed: March 15, 2004
    Publication date: September 9, 2004
    Applicant: Allergan Sales, Inc.
    Inventors: Gary J. Beck, Edward D.S. Kerslake, Orest Olejnik
  • Preserved cyclodextrin-containing compositions
    Patent number: 6723353
    Abstract: Compositions including a liquid medium, a cyclodextrin component and a preservative component which has a reduced tendency to being complexed with the cyclodextrin component. In one embodiment, the preservative component is a chlorite component. Active components, such as pharmaceutically active components or drugs, preferably are included in the compositions.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: April 20, 2004
    Assignee: Allergan, Inc.
    Inventors: Gary J. Beck, Edward D. S. Kerslake, Orest Olejnik
  • Compositions containing alpha-2-adrenergic agonist components
    Publication number: 20040063689
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 1, 2004
    Applicant: Allergan, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake
  • Compositions containing alpha-2-adrenergic agonist components
    Patent number: 6673337
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: January 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Orest Olejnik, Edward D. S. Kerslake
  • Compositions containing alpha-2-adrenergic agonist components
    Patent number: 6641834
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: November 4, 2003
    Assignee: Allergan Sales, Inc.
    Inventors: Orest Olejnik, Edward D. S. Kerslake
  • Compositions containing &agr;-2-adrenergic agonist components
    Patent number: 6627210
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: September 30, 2003
    Assignee: Allergan, Inc.
    Inventors: Orest Olejnik, Edward D. S. Kerslake
  • Compositions containing therapeutically active components having enhanced solubility
    Publication number: 20030153530
    Abstract: Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: February 24, 2003
    Publication date: August 14, 2003
    Applicant: Allergan Sales, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake
  • Compositions containing therapeutically active components having enhanced solubility
    Patent number: 6562873
    Abstract: Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: May 13, 2003
    Assignee: Allergan, Inc.
    Inventors: Orest Olejnik, Edward D. S. Kerslake
  • Compositions containing alpha-2-adrenergic agonist components
    Publication number: 20030087893
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: November 19, 2002
    Publication date: May 8, 2003
    Applicant: Allergan Sales, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake
  • Compositions containing alpha-2-adrenergic agonist components
    Publication number: 20030027811
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: September 6, 2002
    Publication date: February 6, 2003
    Applicant: Allergan Sales, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake
  • Preserved cyclodextrin-containing compositions
    Publication number: 20020076449
    Abstract: Compositions including a liquid medium, a cyclodextrin component and a preservative component which has a reduced tendency to being complexed with the cyclodextrin component. In one embodiment, the preservative component is a chlorite component. Active components, such as pharmaceutically active components or drugs, preferably are included in the compositions.
    Type: Application
    Filed: November 20, 2001
    Publication date: June 20, 2002
    Applicant: Allergan Sales, Inc.
    Inventors: Gary J. Beck, Edward D.S. Kerslake, Orest Olejnik
  • Compositions containing therapeutically active components having enhanced solubility
    Publication number: 20020071874
    Abstract: Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: July 10, 2001
    Publication date: June 13, 2002
    Applicant: Allergan Sales, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake
  • Preserved cyclodextrin-containing compositions
    Patent number: 6358935
    Abstract: Compositions including a liquid medium, a cyclodextrin component and a preservative component which has a reduced tendency to being complexed with the cyclodextrin component. In one embodiment, the preservative component is a chlorite component. Active components, such as pharmaceutically active components or drugs, preferably are included in the compositions.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: March 19, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Gary J. Beck, Edward D. S. Kerslake, Orest Olejnik
  • Compositions containing alpha-2-adrenergic agonist components
    Publication number: 20020032201
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: July 10, 2001
    Publication date: March 14, 2002
    Applicant: Allergan Sales, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake